AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
-5.08 (-4.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close121.00
Bid115.21 x 900
Ask116.47 x 1400
Day's Range115.19 - 120.84
52 Week Range115.19 - 197.00
Avg. Volume2,352,806
Market Cap37.999B
Beta (3Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-21.46
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & Yield2.96 (2.01%)
Ex-Dividend Date2019-05-13
1y Target Est177.60
Trade prices are not sourced from all markets
  • Time to buy ArcelorMittal? Any interest in Alibaba? What about Fitbit? The viewers #AskHalftime
    CNBC Videos27 days ago

    Time to buy ArcelorMittal? Any interest in Alibaba? What about Fitbit? The viewers #AskHalftime

    The "Halftime Report" traders answer viewer questions on ArcelorMittal, Alibaba, Fitbit and Allergan

  • Allergan plc's (NYSE:AGN) Profit Outlook
    Simply Wall St.yesterday

    Allergan plc's (NYSE:AGN) Profit Outlook

    Allergan plc's (NYSE:AGN): Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded...

  • Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
    Zacks2 days ago

    Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

    FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

  • PR Newswire3 days ago

    FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

    THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

  • Pharmaceutical giant Allergan expands in Northwest Austin
    American City Business Journals4 days ago

    Pharmaceutical giant Allergan expands in Northwest Austin

    Apple will be one of Allergan's new neighbors in this Northwest Austin business park. The landlord has invested in a number of upgrades since buying the buildings in 2015.

  • Barrons.com4 days ago

    Short Sellers Are Making Bigger Bets Against Teva and Allergan Stock

    Short sellers are taking a growing interest in the specialty pharmaceutical sector as litigation concerns swirl around Teva and Allergan.

  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalyst4 days ago

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Allergan plc.

    Allergan plc NYSE:AGNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AGN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AGN had net inflows of $3.12 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Allergan plc (AGN) A Good Stock To Buy ?
    Insider Monkey6 days ago

    Is Allergan plc (AGN) A Good Stock To Buy ?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • TherapeuticsMD Enters Agreement to Market Drugs Outside US
    Zacks6 days ago

    TherapeuticsMD Enters Agreement to Market Drugs Outside US

    TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

  • 7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs
    Investopedia9 days ago

    7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs

    As stocks pullback from record highs, lowered market valuations are making a number of companies look like strong potential takeover targets.

  • Allergan (AGN) Down 9.7% Since Last Earnings Report: Can It Rebound?
    Zacks10 days ago

    Allergan (AGN) Down 9.7% Since Last Earnings Report: Can It Rebound?

    Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks11 days ago

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • TheStreet.com13 days ago

    Watch These 9 Companies in a Botox Export Boom Out of South Korea

    South Korea is the capital of K-pop - and plastic surgery. One in three women between the ages of 19 and 29 have had a vanity operation, according to Gallup Korea, although some Koreans say the figure is higher. There is a clutch of nine companies that have started manufacturing or selling botox in Korea.

  • Barrons.com18 days ago

    Johnson & Johnson Stock Falls as Its Opioid Trial Gets Underway

    Johnson & Johnson, like other makers of opioid drugs, is the target of a number of lawsuits for its alleged role in the opioid crisis. The first major trial began this week in Oklahoma.

  • Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
    Zacks18 days ago

    Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression

    Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.

  • Reuters19 days ago

    Allergan to recall textured breast implants in Canada

    Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer. The Botox-maker in December took its textured breast implants off the market in Europe after a French regulatory body ordered a recall. The potential risks associated with the implants outweigh their benefits, including the rare but serious risk of BIA-ALCL, Health Canada said on Tuesday.

  • Reuters19 days ago

    Allergan's Vraylar wins U.S. FDA approval for bipolar depression

    Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday. The drug is expected to bring in sales of $683 million in 2019 and rake in sales of about $1.36 billion by 2026 with the label expansion, Mizuho analyst Irina Koffler said. "The company has a long legacy in depression.

  • Conatus Down More Than 60% in the Past 90 Days: Here's Why
    Zacks19 days ago

    Conatus Down More Than 60% in the Past 90 Days: Here's Why

    Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

  • PR Newswire19 days ago

    Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression

    - New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes - DUBLIN and BUDAPEST, Hungary ...

  • PR Newswire23 days ago

    Allergan Announces Updated Presentation Time at the Bernstein Strategic Decisions Conference

    DUBLIN , May 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35 th Annual Strategic Decisions ...

  • Benzinga24 days ago

    David Tepper To Turn Appaloosa Into A Family Office, Focus On Family And Panthers

    After 26 years, billionaire hedge fund manager David Tepper is shutting down his Appaloosa LP to outside investors. The Wall Street Journal has reported Tepper plans to return outside clients’ money as ...

  • Bloomberg24 days ago

    Micron, PG&E, Allergan, Amazon Among Appaloosa's Top Holdings

    (Bloomberg) -- Appaloosa Management founder David Tepper plans to return money to investors, although the timing hasn’t been finalized yet.

  • PR Newswire24 days ago

    Allergan to Present at the Jefferies 2019 Healthcare Conference

    DUBLIN , May 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Commercial Officer William Meury will participate in a fireside chat at the Jefferies 2019 Healthcare Conference ...

  • He's one of NYC's youngest VCs: Get to know Gen Z investor Patrick Finnegan
    American City Business Journals25 days ago

    He's one of NYC's youngest VCs: Get to know Gen Z investor Patrick Finnegan

    "I am starting to invest in businesses that are not just sexy consumer plays," Finnegan, 22, says.